Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MNKD Stock Forecast 2026-2027
$4.04
Current Price
$1.25B
Market Cap
Buy 7
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MNKD Price Targets
+172.3%
To High Target of $11.00
+73.3%
To Median Target of $7.00
+17.6%
To Low Target of $4.75
MNKD Price Momentum
-4.3%
1 Week Change
+10.4%
1 Month Change
+0.2%
1 Year Change
-28.7%
Year-to-Date Change
-37.9%
From 52W High of $6.51
+81.2%
From 52W Low of $2.23
📊 TOP ANALYST CALLS
Did MNKD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MannKind is one of their latest high-conviction picks.
Latest MNKD Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, MNKD has a bullish consensus with a median price target of $7.00 (ranging from $4.75 to $11.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $4.04, the median forecast implies a 73.3% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Douglas Miehm at RBC Capital, suggesting a 17.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MNKD Analyst Ratings
7
Buy
1
Hold
0
Sell
MNKD Price Target Range
Low
$4.75
Average
$7.00
High
$11.00
Current: $4.04
Latest MNKD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MNKD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2026 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $4.75 |
| May 7, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $10.00 |
| May 7, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $7.00 |
| May 7, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Maintains | $10.00 |
| Apr 28, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Apr 13, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Mar 5, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Feb 27, 2026 | RBC Capital | Sector Perform | Downgrade | $N/A | |
| Feb 27, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 27, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 25, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 26, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 24, 2025 | Truist Securities | Buy | Initiates | $N/A | |
| Nov 11, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Nov 11, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Oct 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 18, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 5, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Sep 3, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Sep 2, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A |
MannKind Corporation (MNKD) Competitors
The following stocks are similar to MannKind based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MannKind Corporation (MNKD) Financial Data
MannKind Corporation has a market capitalization of $1.25B with a P/E ratio of 193.5x. The company generates $360.78M in trailing twelve-month revenue with a -6.6% profit margin.
Revenue growth is +15.1% quarter-over-quarter, while maintaining an operating margin of -3.3% and return on equity of -11.5%.
Valuation Metrics
Market Cap
$1.25B
Enterprise Value
$1.56B
P/E Ratio
193.5x
PEG Ratio
-0.9x
Price/Sales
3.5x
Growth & Margins
Revenue Growth (YoY)
+15.1%
Gross Margin
+80.6%
Operating Margin
-3.3%
Net Margin
-6.6%
EPS Growth
+15.1%
Financial Health
Cash/Price Ratio
+10.7%
Current Ratio
1.9x
Debt/Equity
-7.3x
ROE
-11.5%
ROA
+2.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MannKind Corporation (MNKD) Business Model
About MannKind Corporation
What They Do
Develops innovative inhaled therapies for diseases.
Business Model
The company generates revenue by developing and commercializing inhaled therapies and delivery devices for patients suffering from cardiometabolic and orphan lung diseases. Its key products include inhaled insulin and drug delivery systems, which address specific medical needs and improve patient outcomes. MannKind also advances a pipeline of innovative technologies and has expanded its portfolio through strategic acquisitions.
Additional Information
Founded in 1991 and headquartered in Danbury, Connecticut, MannKind Corporation is committed to addressing unmet medical needs in endocrine and rare pulmonary disorders using its proprietary Technosphere platform. The company focuses on patient-centric solutions and has collaborative partnerships to enhance its product offerings.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
591
CEO
Dr. Michael E. Castagna Pharm.D.
Country
United States
IPO Year
2004
Website
mannkindcorp.comMannKind Corporation (MNKD) Latest News & Analysis
Latest News
Quick Summary
A collaboration focuses on inhaled insulin, enhancing innovation and options for pediatric diabetes care, indicating potential growth in this sector.
Why It Matters
The collaboration highlights potential growth in the inhaled insulin market, signaling innovation in pediatric diabetes care, which could lead to increased revenue and market opportunities for involved companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ADA 2026 showcased key findings on Afrezza® (inhaled insulin) from clinical and real-world studies, focusing on its use in pediatric care, pregnancy, and artificial intelligence-driven applications.
Why It Matters
The findings on Afrezza® suggest potential market expansion in pediatric care and pregnancy, signaling growth opportunities for the company and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MannKind has completed randomization in its Phase 1b INFLO-1 study and has enrolled the first patient in Phase 2 INFLO-2, marking a significant development period for the company.
Why It Matters
MannKind's progress in clinical trials signals potential advancements in product development, which could impact future revenue and stock performance, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MannKind's Afrezza receives FDA approval for pediatric use in children aged 6+ with diabetes. Targeting a 360,000-patient base, it estimates $300–500M revenue potential by 2027.
Why It Matters
MannKind's FDA approval for Afrezza in children opens a significant market, potentially generating $300-$500 million in revenue, enhancing growth prospects and attracting investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
MannKind (NASDAQ: MNKD) announced FDA approval for Afrezza for pediatric patients with diabetes aged 6 and older, expanding its market to children and adolescents.
Why It Matters
FDA approval of Afrezza for pediatric patients expands market potential, potentially increasing sales and profitability for MannKind, which could positively influence stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
The FDA has approved MannKind's inhaled rapid-acting insulin for use in children with diabetes, providing a needle-free treatment option for patients under 18.
Why It Matters
Approval of MannKind's inhaled insulin for children expands market potential, enhances competitive positioning, and may drive revenue growth, impacting stock performance positively.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About MNKD Stock
What is MannKind Corporation's (MNKD) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, MannKind Corporation (MNKD) has a median price target of $7.00. The highest price target is $11.00 and the lowest is $4.75.
Is MNKD stock a good investment in 2027?
According to current analyst ratings, MNKD has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MNKD stock?
Wall Street analysts predict MNKD stock could reach $7.00 in the next 12 months. This represents a 73.3% increase from the current price of $4.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MannKind Corporation's business model?
The company generates revenue by developing and commercializing inhaled therapies and delivery devices for patients suffering from cardiometabolic and orphan lung diseases. Its key products include inhaled insulin and drug delivery systems, which address specific medical needs and improve patient outcomes. MannKind also advances a pipeline of innovative technologies and has expanded its portfolio through strategic acquisitions.
What is the highest forecasted price for MNKD MannKind Corporation?
The highest price target for MNKD is $11.00 from at , which represents a 172.3% increase from the current price of $4.04.
What is the lowest forecasted price for MNKD MannKind Corporation?
The lowest price target for MNKD is $4.75 from Douglas Miehm at RBC Capital, which represents a 17.6% increase from the current price of $4.04.
What is the overall MNKD consensus from analysts for MannKind Corporation?
The overall analyst consensus for MNKD is bullish. Out of 6 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are MNKD stock price projections?
Stock price projections, including those for MannKind Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 3:14 AM UTC